People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

PR Newswire

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level <7% and were more likely to see weight loss of ≥5% vs those who were switched to tirzepatide 2.5 mg or 5 mg with allowed titration up to 15 mg1 This retrospective claims analysis, across >64,000 US adults, offered exploratory insights of patients with type 2 diabetes who were escalated from 1 mg to 2 mg semaglutide vs switching to tirzepatide, in a real-world dose titration1PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026 /PRNewswire/ -- Novo Nordisk today announced new real‑world evidence in adults with type 2 diabetes (T2D) treated with once‑weekly semaglutide 1 mg that examines how escalating to semaglutide 2 mg compares with switching to tirzepatide and supports patient goals for HbA1c and weight loss. By one year, both groups were associated with similar proportions of patients achieving an HbA1c of <7%, and people on semaglutide 2 mg had a statistically significant higher event rate for achieving weight loss ≥5% when compared to people switching to tirzepatide (starting on 2.5 mg or 5 mg with the ability to titrate).1 This retrospective cohort analysis, drawn from a large US claims database (January 2018-September 2025), supports escalating to semaglutide 2 mg as a clinically appropriate and effective treatment strategy.1 These findings will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) on Sunday, June 7.